Blinatumomab + Dexamethasone + Ibrutinib + Nivolumab
Phase 2Terminated 0 views this week 0 watching💤 Quiet
Interest: 27/100
27
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Hematopoietic/Lymphoid Cancer
Conditions
Hematopoietic/Lymphoid Cancer, Richter's Transformation
Trial Timeline
Jun 22, 2017 → Feb 11, 2022
NCT ID
NCT03121534About Blinatumomab + Dexamethasone + Ibrutinib + Nivolumab
Blinatumomab + Dexamethasone + Ibrutinib + Nivolumab is a phase 2 stage product being developed by Amgen for Hematopoietic/Lymphoid Cancer. The current trial status is terminated. This product is registered under clinical trial identifier NCT03121534. Target conditions include Hematopoietic/Lymphoid Cancer, Richter's Transformation.
Hype Score Breakdown
Clinical
12
Activity
0
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03121534 | Phase 2 | Terminated |